Early administration of aripiprazole long-acting injectable in acute inpatients with schizophrenia reduces hospitalization stay
Poster A105, Monday, October%208, 11:30%20am%20-%201:00%20pm, Essex%20Ballroom
Santiago Ovejero1, Raquel Alvarez2, Nora Palomar1, Marta Migoya1, Fanny Cegla1, Laura Mata1, Sergio Sanchez-Alonso1; 1Hospital Universitario Fundacion Jimenez Diaz, Madrid, 2Hospital Universitario Rey Juan Carlos, Mostoles
Objectives: A naturalistic study on the use of aripiprazole long-acting injectable (LAI) in acute inpatients with schizophrenia of two hospitals is presented. Methods: In this study, 51 inpatients (30 men, 21 women) with schizophrenia were treated with aripiprazole LAI; in 1 patient this treatment was removed before discharge because of lack of efficacy. 49% of patients had a damaging drug consumption (56% of them consumed cannabis). Results: The average hospital stay (HS) was 21 days. The HS was smaller when the dose of aripiprazole LAI was administered earlier (linear regression; r<.0001). When the dose of aripiprazole LAI was administered in the first week of admission the HS was 16.3 days, in comparition when administered over a week, 28.4 days (t test; p<.0001). At discharge, mean dose of aripiprazole LAI was 404 mg. Conclusions: In this sample, aripiprazole LAI is a effective treatment for acute inpatients with schizophrenia and a short average HS is observed. The early use of aripiprazole LAI, in the first week of admission, reduces HS.
Topic Area: Psychopharmacology